Clinical trial to assess effectiveness of urological tests in men
Press release issued: 17 March 2015
For the first time ever, a major new clinical trial, led by the Bristol Urological Institute at Southmead Hospital Bristol, aims to assess the clinical and cost effectiveness of urological tests in men who have difficulty passing urine. The trial is being managed by the Bristol Randomised Trials Collaboration at the University of Bristol’s School of Social and Community Medicine.
As they get older, some men develop problems and difficulties passing urine. This may be for a number of reasons including an enlarged prostate gland – which narrows the bladder outlet (urethra), or because the bladder becomes less able to contract.
Prostate surgery is more likely to help symptoms in the first group of patients, while the second group may have no improvement after surgery and this could be wrong for them due to risk of complications including incontinence. Urodynamics involves putting a small tube (catheter) into the bladder via the penis, and another into the rectum, to measure bladder and abdominal pressures while the bladder is filled with a sterile fluid. The procedure is considered safe, but some men find it uncomfortable or undignified, and a few develop urine infection afterwards.
Urodynamics can measure some aspects of bladder function, such as bladder pressures during filling and voiding, and bladder outlet obstruction pressures.
Consultant Urologist Marcus Drake, who will lead the trial, said: “We think that it could be useful to select the men who should and should not have surgery. However, no studies have been conducted so far to tell us if this is true. This study is designed to find out if the invasive tests are worthwhile.
“UPSTREAM is a randomised controlled trial in men who have bothersome difficulty passing urine and who are considering having surgery for their symptoms.”
Men who are willing and eligible to take part will be asked to complete routine assessments which includes a bladder diary and questionnaires which provides a measure of the relevant symptoms, have a physical examination, carry out flow rate testing and their urine will be tested for infection. Half of the men will also have the Urodynamics test. After all the tests are done, the urologist will review them, and the men will decide what treatment they then wish to have.
The study will be run in urology departments of at least 19 NHS hospitals.
The group studied will be men who continue to be bothered by difficulty passing urine, despite initial treatment such as drugs, and who are seeking further treatment, for example surgery.
Men will not be invited to take part if they:
• Are unable to pass urine without a catheter (urinary retention);
• Have a relevant neurological disease, such as a stroke;
• Are undergoing treatment for prostate or bladder cancer;
• Have previously had prostate surgery;
• Are not medically fit for surgery, or are unable to complete outcome assessments;
• Do not consent to be assigned at random to one of the pathways.
Mr Drake added: “We will compare the two methods of investigation by finding out whether the men had similar relief of their symptoms, by measuring the change in the prostate symptom score in the two groups at 18 months after randomisation. We will also look at whether the Urodynamics tests changed the decision for surgery in some of the men, the cost effectiveness of the two pathways and urinary symptoms and quality life at various intervals.”
The four-year study will comprise a setting-up phase of six months, 18-months recruitment, 18-months follow-up and six months data analysis and communication of results.
The UPSTREAM team based in the Bristol Randomised Trials Collaboration (BRTC), within the University of Bristol’s Bristol Medical School: Population Health Sciences, will be responsible for the day-to-day management of study activities. They will provide overall methodological support for the design, conduct and analysis of the study.
The study will be supported by an independent Trial Steering Committee, a Patient Involvement Panel and a Data Monitoring Committee. The information will be important for men trying to decide on management of their symptoms, for the doctors advising them, and for the NHS in ensuring best use is made of resources for this common problem.
Marcus Drake is Consultant Senior Lecturer in the University of Bristol’s Bristol Medical School: Translational Health Sciences and Senior Lecturer in the University’s School of Physiology, Pharmacology and Neuroscience .
You can keep up-to-date with the trial’s progress on Twitter @UPSTREAM_trial.
This project was funded by the National Institute for Health Research HTA programme (project number 12/140/01).
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS or the Department of Health.
The National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme funds research about the effectiveness, costs, and broader impact of health technologies for those who use, manage and provide care in the NHS. It is the largest NIHR programme and publishes the results of its research in the Health Technology Assessment journal, with over 700 issues published to date. The journal’s 2013 Impact Factor (5.116) ranked it two out of 85 publications in the Health Care Sciences and Services category. All issues are available for download, free of charge, from the website. The HTA Programme is funded by the NIHR, with contributions from the CSO in Scotland, NISCHR in Wales, and the HSC R&D Division, Public Health Agency in Northern Ireland.
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world.
This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.